AnalysisNews

YARW today

$12.90-$1.33 (-9.35%)close Nov 20, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bearish

1 hourSymmetric Triangle

15 minStrong Bearish

5 minStrong Bearish

Daily trend turns up above $20.65

Key levels

Resistance$24.00

Resistance$19.92

Support$12.38

Latest news & SEC filings

DealYarrow Bioscience wraps up $172.5M share sale

AnalystJefferies starts Yarrow Bioscience coverage with Buy rating and $40 price target

All YARW news →

About Yarrow Bioscience

Yarrow Bioscience is a drug developer in the clinical testing phase, working on treatments for inflammation and immune system disorders. Its main candidate, YB-101, is an antibody targeting TSHR for Graves Disease and Thyroid Eye Disease. The company also owns global rights to BET inhibitor compounds, including the oral BD2-selective VYN202 and the topical pan-BD repibresib. Manufacturing is handled by outside contractors, and no products are sold yet.

Based on the company's 10-K filed Feb 27, 2026.

Nasdaq · Healthcare

Yarrow Bioscience, Inc. (YARW)

$14.23-0.12 (-0.84%)
WATCHLISTGrade: B+Risk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
14.9216.2417.5718.8914.23Oct 19Oct 27Nov 4Nov 12
High14.83
Low13.79
Open14.33
Volume148K
Avg Vol160K
VWAP14.17
30d High20.21
30d Low13.60
30d Chg-27.80%

What Is the Price Target for YARW?

SEPT Low Target

$58.00

SEPT Mid Target

$59.00

SEPT High Target

$60.00

Analyst Consensus

$59.00

Current: $14.23Upside: +314.6%Confidence: 40%Method: Analyst Consensus

Is YARW a Buy or Sell Right Now?

72
Investability Score
WATCHLIST12-18 months

Thesis

  • •Revenue growing 13.8% YoY with ACCELERATING trend — accelerating momentum.

Test your own strategy on YARW

Describe your strategy in plain words, then scan, alert, backtest and paper trade it on YARW with SEPT’s own market data.

Start Free Trial →

Is YARW Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

Analyst Consensus

Fair Value

$59.00

27

Moat Score

NONE

3/9

Piotroski Score

128.6

Altman Z-Score

What Is Smart Money Doing with YARW?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See Smart Money Data →

YARW Growth Story

Revenue YoY

13.8%

3yr Revenue CAGR

6.1%

EPS Growth YoY

33.33%

FCF Growth YoY

2.8%

Revenue Trend

ACCELERATING

Dark Pool Trades for YARW

PREVIEW

Recent off-exchange (dark pool) prints for YARW: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.

TimePriceSizeValueSide
20:48:29$14.161,000$$14KBUY
16:53:42$14.221,200$$17KBUY
16:53:39$14.191,752$$25KSELL
16:29:06$14.237,933$$113KSELL
15:35:08$13.931,735$$24KMIDPOINT

5 dark pool trades shown · $$193K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

What Traders Are Saying About YARW

3 posts

SEPT Investing hosts an active trader community sharing real-time analysis, trade setups, and market discussion for YARW. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.

C
Chloe22h ago

$YARW: Logos Global Management LP and affiliates filed a Schedule 13G/A on Tue Nov 17, reporting beneficial ownership of about 9.99% of Yarrow Bioscience common stock, shares plus prefunded warrants u...

7 views
T
tape_investor462d ago

$YARW: ADAR1 Capital Management, LLC and its sole manager Daniel Schneeberger filed an amended Schedule 13G on Mon Nov 16, reporting beneficial ownership of 282,996 shares, or 2.5%, of Yarrow Bioscien...

15 views
E
Elif P.2d ago

$YARW: venBio Global Strategic Fund V, L.P. filed a Schedule 13G/A on Mon Nov 16 reporting beneficial ownership of approximately 9.99% of common stock, per the filing. 📄

16 views

Join traders discussing YARW in real-time

Trade ideas, setups, dark pool alerts, and AI-powered analysis

Join the discussion

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Yarrow Bioscience, Inc. (YARW) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Your strategy, tested before real money.

Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.

Try SEPT Free for 7 Days →

YARW — frequently asked questions

What is YARW stock price today?

Yarrow Bioscience, Inc. (YARW) is at $12.90, down 9.35% (-$1.33) at the Nov 20, 2026 close.

Why is YARW stock moving today?

Latest YARW news — Nov 16, 2026: Yarrow Bioscience wraps up $172.5M share sale · Nov 16, 2026: Jefferies starts Yarrow Bioscience coverage with Buy rating and $40 price target

What is the YARW price target?

The average analyst price target for YARW is $59.00, ranging from $58 to $60, based on 2 analysts. Latest: Guggenheim initiates on Nov 6, 2026.

What do analysts rate YARW?

Analyst ratings for YARW: 0 Buy, 3 Hold, 0 Sell — consensus Hold.

Did YARW beat earnings?

YARW last reported on Aug 13, 2026: EPS -$2.14 vs -$11.00 expected — a beat of 80.5%.

How much debt does YARW have?

Yarrow Bioscience, Inc. reported $0M of debt and $23M of cash (Jun 30, 2026).

What are YARW support and resistance levels?

Support: $12.38. Resistance: $19.92, $24.00, $27.31.

What are insiders doing with YARW?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on YARW?

Nov 16, 2026: Yarrow Bioscience wraps up $172.5M share sale · Nov 16, 2026: Jefferies starts Yarrow Bioscience coverage with Buy rating and $40 price target